Skip to main content
Fig. 1 | Reproductive Biology and Endocrinology

Fig. 1

From: Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

Fig. 1

Study Design Showing Cycle 2 (Panel A) and Cycle 3 (Panel B) of Ovaleap® Treatment. a Ovaleap® Cycle 2. b Ovaleap® Cycle 3. d, days; hCG, human chorionic gonadotropin; V1, Visit 1; V2, Visit 2; V3, Visit 3; V4, Visit 4; W 12, Week 12. aThe duration of Ovaleap® treatment was at the discretion of the investigator

Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us